Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes

77Citations
Citations of this article
102Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Background: The kidney plays an important role in glucose metabolism, and has been considered a target for therapeutic intervention. The sodium-glucose cotransporter type 2 (SGLT2) mediates most of the glucose reabsorption from the proximal renal tubule. Inhibition of SGLT2 leads to glucosuria and provides a unique mechanism to lower elevated blood glucose levels in diabetes. The purpose of this review is to explore the physiology of SGLT2 and discuss several SGLT2inhibitors which have clinical data in patients with type 2 diabetes. Methods: We performed a PubMed search using the terms "SGLT2" and "SGLT2inhibitor" through April 10, 2012. Published articles, press releases, and abstracts presented at national and international meetings were considered. Results: SGLT2inhibitors correct a novel pathophysiological defect, have an insulin-independent action, are efficacious with glycosylated hemoglobin reduction ranging from 0.5% to 1.5%, promote weight loss, have a low incidence of hypoglycemia, complement the action of other antidiabetic agents, and can be used at any stage of diabetes. They are generally well tolerated. However, due to side effects, such as repeated urinary tract and genital infections, increased hematocrit, and decreased blood pressure, appropriate patient selection for drug initiation and close monitoring after initiation will be important. Results of ongoing clinical studies of the effect of SGLT2inhibitors on diabetic complications and cardiovascular safety are crucial to determine the risk-benefit ratio. A recent decision by the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of dapagliflozin for the treatment of type 2 diabetes as an adjunct to diet and exercise, in combination with other glucose-lowering medicinal products, including insulin, and as a monotherapy for metformin-intolerant patients. Clinical research also remains to be carried out on the long-term effects of glucosuria and other potential effects of SGLT2inhibitors, especially in view of the observed increase in the incidence of bladder and breast cancer. SGLT2inhibitors represent a promising approach for the treatment of diabetes, and could potentially be an addition to existing therapies. © 2012 Kim and Babu, publisher and licensee Dove Medical Press Ltd.

Cite

CITATION STYLE

APA

Kim, Y., & Babu, A. R. (2012). Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity. Dove Medical Press Ltd. https://doi.org/10.2147/dmso.s22545

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free